Rafael Fonseca: Defining CRS and ICANs risks

Rafael Fonseca shared a post by USMIRC News, on X:

“Clearly defines risk of CRS and ICANs in the first two weeks. No need to have patients stick around for a month closer to treatment centers and impose driving restrictions – for what?”

Quoting USMIRC News‘s post:

“Timing of Toxicities and Non-relapse Mortality Following CAR T Therapy in Myeloma.’

Authors: William Wesson, Danai Dima, Nahid Suleman, Md Saiful Islam Saif, Carine Tabak, Emerson Logan, James A. Davis, Mary McGann, Fateeha Furqan, Meera Mohan, Aliya Rashid, Al–Ola Abdallah, Fauzia Ullah, Leyla Shune, Muhammad Umair Mushtaq, Shahzad Raza, Joseph McGuirk, Mehdi Hamadani, Faiz Anwer, Hamza Hashmi Nausheen Ahmed.”

Source: Rafael Fonseca/X and USMIRC News/X

Dr. Rafael Fonseca, M.D., is a hematologist at Mayo Clinic, specializing  in multiple myeloma and related conditions.. Dr. Fonseca’s expertise extends to diagnosing and treating plasma cell disorders, leading clinical trials that have advanced myeloma treatment.

He has led research on genetic markers in myeloma. Dr. Fonseca has received numerous awards and honors, including the Damon Runyon-Walter Winchell Clinical Investigator Award and the International Waldenström Macroglobulinemia Research Award.